1-12 of 12
E O'Brien
Close
Sort by
Journal Articles

Patient-Reported Outcomes Among Patients with High-Risk Untreated Follicular Lymphoma (FL) Randomized to Bendamustine/Rituximab (BR) or Bendamustine/Rituximab with Bortezomib (BVR) Therapy: Results from the ECOG-ACRIN E2408 Study

Giselle K. Perez, PhD, Fangxin Hong, PhD, Andrew M. Evens, DO,MMSc, Thomas M. Habermann, MD, Ranjana Advani, MD, Stephen M. Ansell, MD PhD, Puneet S. Cheema, MD, Philip A. Dy, MD, Timothy E. O'Brien, MD, Jane N. Winter, MD, Julie E. Chang, MD, David Cella, PhD, Brad S. Kahl, MD, Lynne I. Wagner, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 45–46.
https://doi.org/10.1182/blood-2020-140502
Published: 2020
Journal Articles

Analysis of Racial Differences in the Incidence of a Targetable Biomarker, t(11;14), in Patients with Multiple Myeloma

Fang Liu, MD, Jeries Kort, MD, Shashirekha Shetty, PhD, Ravikumar Kyasaram, John Shanahan, Timothy E. O'Brien, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 1–2.
https://doi.org/10.1182/blood-2020-140133
Published: 2020
Journal Articles

Risk of Secondary Malignancy in CLL Patients Treated with Novel Targeted Agents

Anna Eversman, Shufen Cao, Kirsten M Boughan, DO, Molly M Gallogly, MDPhD, Ehsan Malek, MD, Leland Metheny, III, MD, Timothy E. O'Brien, MD, Folashade Otegbeye, MBBChir,MPH, Brenda W. Cooper, MD, Pingfu Fu, Marcos de Lima, MD, Paolo F Caimi, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 46–47.
https://doi.org/10.1182/blood-2020-140042
Published: 2020
Journal Articles

Under Reporting of Patient Reported Outcomes (PROs) in Myeloproliferative Neoplasm (MPN) Clinical Trials

Anthony J Messina, MSc, Quentin E O'Brien, MPH, Vasily Andrianov, MD, Keren R. Moss, MD, Laura Vidal, MD, Liat Vidal-Fisher, MD MSc
Journal: Blood
Blood (2019) 134 (Supplement_1): 4754.
https://doi.org/10.1182/blood-2019-128741
Published: 2019
Journal Articles

Quantification of Schistocytes from the Peripheral Blood Smear in Thrombotic Thrombocytopenic Purpura (TTP) Compared to Non-TTP Thrombocytopenic Hospitalized Patients

Timothy E. O'Brien, MD, Lynda Bowman, BS, Augustine Hong, Krishna Goparaju, MD BA
Journal: Blood
Blood (2018) 132 (Supplement 1): 4983.
https://doi.org/10.1182/blood-2018-99-114159
Published: 2018
Journal Articles

Incidence of Neutropenic Fever at a Safety Net Hospital in Cancer Chemotherapy Patients Receiving Prophylactic Pegfilgrastim Manual Injection Compared to the on-Body Auto-Injector

Atin Jindal, MD, Jan Kover, BPharm, Vanja Raduka, PharmD, R.Ph, Timothy E. O'Brien, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4709.
https://doi.org/10.1182/blood-2018-99-114282
Published: 2018
Journal Articles

A 3-Arm Randomized Phase II Trial with Bendamustine/Rituximab Therapy in Untreated High Risk (HR) Follicular Lymphoma (FL): Bortezomib Induction or Novel IMiD ® Continuation (BIONIC) Study from the ECOG-ACRIN Cancer Research Group

Andrew M Evens, DO,MSc, Fangxin Hong, PhD, Thomas M Habermann, MD, Ranjana H. Advani, MD, Randy D. Gascoyne, MD, Thomas E Witzig, MD, Andrew Quon, MD, Erik A. Ranheim, MD PhD, Puneet Cheema, MD, Philip Dy, MD, Timothy E. O'Brien, MD, Jane N. Winter, MD, Terrence Paul Cescon, Julie Chang, MD, Brad S Kahl, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 482.
https://doi.org/10.1182/blood.V130.Suppl_1.482.482
Published: 2017
Journal Articles

Risk-Adapted Therapy in Adults with Burkitt Lymphoma: Results of NCI 9177, a Multicenter Prospective Phase II Study of DA-EPOCH-R

Mark Roschewski, MD, Kieron Dunleavy, MD, Jeremy S. Abramson, MD MMSc, Brian K Link, MD, Samir Parekh, MD, Deepa Jagadeesh, MDMPH, Philip Bierman, MD, Ronald T. Mitsuyasu, MD, Ramakrishna Battini, MD, Peter R. Watson, MD, David Peace, MD, Wahid Hanna, MD, Bayard L. Powell, MD, Timothy E. O'Brien, MD, David King, MD, Christopher Melani, MD, Andrea Lucas, RN, Seth M. Steinberg, PhD, Brad S Kahl, MD, Jonathan W. Friedberg, MD, Richard F. Little, MDMPH, Nancy L. Bartlett, MD, Michelle A. Fanale, MD, Ariela Noy, MD, Wyndham H. Wilson, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 188.
https://doi.org/10.1182/blood.V130.Suppl_1.188.188
Published: 2017
Journal Articles

Pegfilgrastim Use and Risk of Bleomycin Induced Pulmonary Toxicity in Hodgkin Lymphoma

David Yao, MD PhD, Murali Janakiram, MD, Timothy E. O'Brien, MD
Journal: Blood
Blood (2016) 128 (22): 5350.
https://doi.org/10.1182/blood.V128.22.5350.5350
Published: 2016
Journal Articles

Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia

Brief Report
Lewis B. Silverman, Jeffrey G. Supko, Kristen E. Stevenson, Christina Woodward, Lynda M. Vrooman, Donna S. Neuberg, Barbara L. Asselin, Uma H. Athale, Luis Clavell, Peter D. Cole, Kara M. Kelly, Caroline Laverdière, Bruno Michon, Marshall Schorin, Cindy L. Schwartz, Jane E. O'Brien, Harvey J. Cohen, Stephen E. Sallan
Journal: Blood
Blood (2010) 115 (7): 1351–1353.
https://doi.org/10.1182/blood-2009-09-245951
Published: 2010
Journal Articles

Pegfilgrastim Use and Risk of Bleomycin Induced Pulmonary Toxicity in Hodgkin Lymphoma

Murali Janakiram, MD, Timothy E. O’Brien, MD
Journal: Blood
Blood (2008) 112 (11): 4950.
https://doi.org/10.1182/blood.V112.11.4950.4950
Published: 2008
Journal Articles

Abnormalities in the mechanical properties of red blood cells caused by Plasmodium falciparum

GB Nash, E O'Brien, EC Gordon-Smith, JA Dormandy
Journal: Blood
Blood (1989) 74 (2): 855–861.
https://doi.org/10.1182/blood.V74.2.855.855
Published: 1989